Jupiter Topco LLC Purchases Shares of 34,264 Pediatrix Medical Group, Inc. $MD

Jupiter Topco LLC purchased a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 34,264 shares of the company’s stock, valued at approximately $868,000.

Other large investors have also recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new position in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $33,000. Transamerica Financial Advisors LLC purchased a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Pediatrix Medical Group during the fourth quarter worth $33,000. TD Private Client Wealth LLC acquired a new position in Pediatrix Medical Group during the fourth quarter worth $39,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Pediatrix Medical Group during the fourth quarter worth $43,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MD. Truist Financial lifted their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. UBS Group raised their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Jefferies Financial Group lowered shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price target for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. Finally, Weiss Ratings cut shares of Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 25th. Six equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and a consensus price target of $26.60.

Pediatrix Medical Group Stock Up 0.6%

MD stock opened at $27.03 on Friday. The company’s 50 day moving average price is $26.32 and its 200 day moving average price is $23.37. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of 12.93 and a beta of 0.64. Pediatrix Medical Group, Inc. has a fifty-two week low of $15.69 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company had revenue of $487.78 million during the quarter, compared to the consensus estimate of $478.49 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.